학술논문
Clinical importance of anti-Ro52 antibody for polymyositis and dermatomyositis.
Document Type
Academic Journal
Author
Sugita T; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Tsuboi H; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Sugita N; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Akiyoshi R; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Kuroda Y; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Kawashima A; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Kawashima F; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Tabuchi D; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Honda F; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Ohyama A; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Abe S; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Kitada A; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Asashima H; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Miki H; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Hagiwara S; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Kondo Y; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.; Matsumoto I; Department of Rheumatology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Source
Publisher: Oxford University Press Country of Publication: England NLM ID: 100959226 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-7609 (Electronic) Linking ISSN: 14397595 NLM ISO Abbreviation: Mod Rheumatol Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: To clarify clinical features of anti-Ro52 antibody (Ab)-positive polymyositis (PM)/dermatomyositis (DM).
Patients and Methods: We retrospectively examined clinical features and status of anti-Ro52 Ab in patients with PM/DM admitted at the University of Tsukuba Hospital between January 2019 and February 2023. We compared anti-Ro52 Ab-positive and -negative groups.
Results: A total of 40 patients were selected and analyzed. Median age at diagnosis was 61.5 (48.8-69.3) years and 34 cases were female. Twenty-three cases were PM and 17 cases were DM (including 6 clinically amyopathic dermatomyositis: CADM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease (ILD) was detected in 29 cases, 9 of which were rapidly progressive. Glucocorticoid (GC)-resistant cardiomyopathy was detected in 6 cases, malignancy in 3 cases, and Sjögren's syndrome (SS) in 4 cases. Of the 22 anti-Ro52 Ab positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and -negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), ILD (95.5% vs. 44.4%), GC-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein (CRP) were significantly higher in the anti-Ro52 Ab-positive group (p<0.05). The frequencies of PM/DM, positivity of anti-MDA5 Ab, malignancies, and SS were comparable between groups.
Conclusion: Anti-Ro52 Ab were frequently positive in PM/DM and anti-Ro52 Ab-positive patients showed significantly higher rates of anti-ARS Ab positivity and ILD, GC-resistant cardiomyopathy, concomitant use of immunosuppressants, and higher levels of CRP. Anti-Ro52 Ab may be useful as a severity marker in PM/DM.
(© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)
Patients and Methods: We retrospectively examined clinical features and status of anti-Ro52 Ab in patients with PM/DM admitted at the University of Tsukuba Hospital between January 2019 and February 2023. We compared anti-Ro52 Ab-positive and -negative groups.
Results: A total of 40 patients were selected and analyzed. Median age at diagnosis was 61.5 (48.8-69.3) years and 34 cases were female. Twenty-three cases were PM and 17 cases were DM (including 6 clinically amyopathic dermatomyositis: CADM). Twenty-two cases were positive for anti-Ro52 Ab, 14 for anti-ARS Ab, and 6 for anti-MDA5 Ab. Interstitial lung disease (ILD) was detected in 29 cases, 9 of which were rapidly progressive. Glucocorticoid (GC)-resistant cardiomyopathy was detected in 6 cases, malignancy in 3 cases, and Sjögren's syndrome (SS) in 4 cases. Of the 22 anti-Ro52 Ab positive cases, only 3 were single-positive and the remaining 19 cases simultaneously had other autoantibodies. Comparing the anti-Ro52 Ab-positive and -negative groups, the frequencies of anti-ARS Ab positivity (63.6% vs. 0%), ILD (95.5% vs. 44.4%), GC-resistant cardiomyopathy (27.3% vs. 0%), concomitant use of immunosuppressants (95.5% vs. 55.6%), and levels of C-reactive protein (CRP) were significantly higher in the anti-Ro52 Ab-positive group (p<0.05). The frequencies of PM/DM, positivity of anti-MDA5 Ab, malignancies, and SS were comparable between groups.
Conclusion: Anti-Ro52 Ab were frequently positive in PM/DM and anti-Ro52 Ab-positive patients showed significantly higher rates of anti-ARS Ab positivity and ILD, GC-resistant cardiomyopathy, concomitant use of immunosuppressants, and higher levels of CRP. Anti-Ro52 Ab may be useful as a severity marker in PM/DM.
(© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)